SignalCorporate
Can Redwire's Microgravity Pharma Work Create New Revenue Streams?
Redwire's microgravity pharma work could create new revenue streams.
Context
What happened: Redwire Corporation RDW is expanding its microgravity business into pharmaceutical research and development through its PIL-BOX platform, which lets researchers grow protein-based pharmaceutical crystals in microgravity.
Key numbers: Redwire had launched 42 PIL-BOXes through Dec. 31, 2025.
Why it matters: During 2025 Redwire entered a licensing agreement with ExesaLibero Pharma for royalties on commercial sales of resulting products, a potential new revenue stream. Bristol Myers Squibb BMY and Eli Lilly LLY are also exploring microgravity drug research.
Market: +0.1% by next close ($59.58 on Oct 8), +12.0% YTD
What changed
Redwire Corporation RDW is expanding its microgravity business into pharmaceutical research and development through its PIL-BOX platform, which lets researchers grow protein-based pharmaceutical crystals in microgravity.
Why it matters
During 2025 Redwire entered a licensing agreement with ExesaLibero Pharma for royalties on commercial sales of resulting products, a potential new revenue stream. Bristol Myers Squibb BMY and Eli Lilly LLY are also exploring microgravity drug research.
Market: +0.1% by next close ($59.58 on Oct 8), +12.0% YTD